
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| THEELIN | Parkedale Pharmaceuticals | N-003977 DISCN | 1982-01-01 | 3 products |
Code | Description |
|---|---|
| J1435 | Injection, estrone, per 1 mg |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | 22 | 28 | 46 | 66 | 96 | 248 |
| Female infertility | D007247 | EFO_0008560 | N97 | 10 | 4 | 7 | 6 | 32 | 57 |
| Contraception | D003267 | — | — | 8 | 9 | 18 | 15 | 5 | 54 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 3 | 3 | 8 | 7 | 30 | 50 |
| Healthy volunteers/patients | — | — | — | 34 | 1 | 4 | 1 | 4 | 43 |
| Syndrome | D013577 | — | — | 2 | 4 | 5 | 3 | 16 | 29 |
| Fertilization in vitro | D005307 | — | — | 1 | 3 | 3 | 12 | 10 | 28 |
| Ovulation induction | D010062 | — | — | 3 | 7 | 5 | 4 | 6 | 24 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 6 | 5 | 2 | 1 | 11 | 21 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 4 | 2 | 1 | 8 | 17 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometriosis | D004715 | EFO_0001065 | N80 | 2 | 1 | 2 | — | 13 | 17 |
| Premature menopause | D008594 | — | E28.31 | 3 | 2 | 1 | — | 9 | 13 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | — | 10 | 11 |
| Neoplasms | D009369 | — | C80 | 5 | 1 | 1 | — | 3 | 9 |
| Helping behavior | D006379 | — | — | — | 1 | 6 | — | 1 | 8 |
| Lymphoma | D008223 | — | C85.9 | 3 | 4 | 1 | — | 2 | 8 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | 4 | 1 | — | — | 7 |
| Male infertility | D007248 | EFO_0004248 | N46 | 1 | 1 | 2 | — | 4 | 7 |
| Premenstrual syndrome | D011293 | — | N94.3 | — | 2 | 4 | — | 1 | 7 |
| Papillary thyroid cancer | D000077273 | — | — | 2 | 3 | 1 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian reserve | D065851 | EFO_0004770 | — | — | 1 | — | — | 5 | 6 |
| Premature birth | D047928 | EFO_0003917 | O60 | 2 | 1 | — | — | 3 | 5 |
| Metrorrhagia | D008796 | — | N92.1 | — | 3 | — | — | 2 | 5 |
| Leiomyoma | D007889 | — | D25 | 1 | 1 | — | — | 2 | 3 |
| Follicular lymphoma | D008224 | — | C82 | 1 | 2 | — | — | 1 | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | 1 | — | — | — | 2 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 1 | — | — | — | 2 |
| Hemostasis | D006487 | — | — | — | 1 | — | — | 1 | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | — | 2 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 2 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 9 | — | — | — | — | 9 |
| Pharmacokinetics | D010599 | — | — | 5 | — | — | — | — | 5 |
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Overweight | D050177 | — | E66.3 | 2 | — | — | — | 2 | 4 |
| Hiv | D006678 | — | O98.7 | 1 | — | — | — | 2 | 3 |
| Male breast neoplasms | D018567 | — | — | 1 | — | — | — | 2 | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | — | — | — | — | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | 2 | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 3 | — | — | — | — | 3 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | — | — | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menstrual cycle | D008597 | — | — | — | — | — | — | 6 | 6 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 6 | 6 |
| Fertility | D005298 | — | — | — | — | — | — | 5 | 5 |
| Ovarian cysts | D010048 | — | N83.1 | — | — | — | — | 3 | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 3 | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 3 | 3 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 3 | 3 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 2 | 2 |
| In vitro oocyte maturation techniques | D059471 | — | — | — | — | — | — | 2 | 2 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 2 | 2 |
| Drug common name | Estrone |
| INN | estrone |
| Description | Estrone is a 17-oxo steroid that is estra-1,3,5(10)-triene substituted by an hydroxy group at position 3 and an oxo group at position 17. It has a role as an estrogen, a bone density conservation agent, an antineoplastic agent, a human metabolite and a mouse metabolite. It is a 3-hydroxy steroid, a phenolic steroid, a member of phenols and a 17-oxo steroid. It derives from a hydride of an estrane. |
| Classification | Small molecule |
| Drug class | estrogens |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O |
| PDB | — |
| CAS-ID | 53-16-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1405 |
| ChEBI ID | 17263 |
| PubChem CID | 5870 |
| DrugBank | DB00655 |
| UNII ID | 2DI9HA706A (ChemIDplus, GSRS) |






